To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

July 20, 2018

Today's Rundown

Featured Story

PTC inks $200M Agilis takeover to snag late-phase gene therapy

PTC Therapeutics is paying $200 million upfront to acquire Agilis Biotherapeutics. The deal gives PTC ownership of a gene therapy treatment for rare neurotransmitter disease AADC deficiency that is set to go before the FDA next year.

Top Stories

Roche, PureTech team up to develop oral antisense oligonucleotides

Roche has struck a deal with PureTech Health to develop oral antisense oligonucleotides. The pact gives Roche access to PureTech’s milk-derived exosome technology in return for up to $36 million (€31 million) in near-term payments and milestones that could top out above $1 billion.

Patient death prompts FDA hold on Mersana’s lead cancer ADC

Another antibody-drug conjugate has been stalled by concerns over safety. The FDA has placed a partial hold on Mersana’s lead candidate XMT-1522 after a patient death in a phase 1 trial, causing its shares to plunge.

EuroBiotech Report—Sanofi, Novartis and Gilead strike deals, Amgen-UCB and Brexit

In this week's EuroBiotech Report, European drug developers strike a string of deals, UCB refiles romosozumab and more. 

FiercePharmaAsia—Pfizer Indian plant hassle, China-India pharma bond, Sinovant debut

Pfizer halts production at a legacy Hospira India injectables plant after the FDA cited it for a third time; China is working to grant greater access to Indian drugs amid a U.S. trade war; Vivek Ramaswamy's Roivant Sciences just unveiled Sinovant, a China-focused firm with 11 assets; and more.

Chutes & Ladders—Human Longevity CFO/COO departs after scandal

Human Longevity CFO/COO Nino Fanlo departed after a scandal at his former employer, Sangamo lost another top executive and McCann Health fired its chief creative officer for a conduct code violation. Those moves plus more hirings, firings and retirings throughout the industry.

Resources

[Whitepaper] Building the Business Case for RIM Transformation

Ready to modernize your RIM environment? Secure buy-in with these tips.

[Whitepaper] How early planning and a unified data platform can cut trial timelines and cost.

Accelerate Clinical Research as Study Complexity Grows

[Whitepaper] eClinical Landscape Study - CRO Report from Tufts Center for the Study of Drug Development

See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs).

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

Life science companies are experiencing a significant transformation in how they bring new products to market.

[Whitepaper] Rise in Targeted Therapies Drives Needs for Small Volume Manufacturing

Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing? Here are some ideas to consider when developing a new manufacturing strategy.

Events

.